{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:08:12Z","timestamp":1784005692598,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021316","name":"AstraZeneca United States","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016957","name":"Mirati Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Blueprint Medicine"},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Takeda"},{"name":"Janssen"},{"name":"Summit Therapeutics"},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eli Lilly"},{"name":"Lyell Immunopharma"},{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Children's Hospital of Philadelphia Department of Radiology startup funding"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Apexigen"},{"name":"Lovance"},{"name":"Chemocentryx"},{"name":"Signatero"},{"name":"Gigagen"},{"name":"GI reviewers"},{"name":"Pliant Therapeutics"},{"name":"Esai"},{"name":"Invox"},{"name":"Wherewolf"},{"name":"Monteris Medical"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s11060-024-04754-8","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T15:02:33Z","timestamp":1720105353000},"page":"555-561","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Patterns of brain metastases response to immunotherapy with pembrolizumab"],"prefix":"10.1007","volume":"169","author":[{"given":"Amit","family":"Mahajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanwar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam S.","family":"Aboian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet M.","family":"Kluger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica L.","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"key":"4754_CR1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","volume":"14","author":"L Nayak","year":"2012","unstructured":"Nayak L, Lee EQ, Wen PY (2012) Epidemiology of brain metastases. Curr Oncol Rep 14:48\u201354. https:\/\/doi.org\/10.1007\/s11912-011-0203-y","journal-title":"Curr Oncol Rep"},{"key":"4754_CR2","first-page":"241","volume":"54","author":"D Mathieu","year":"2007","unstructured":"Mathieu D, Kondziolka D, Cooper PB et al (2007) Gamma knife radiosurgery for malignant melanoma brain metastases. Clin Neurosurg 54:241\u2013247","journal-title":"Clin Neurosurg"},{"key":"4754_CR3","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.currproblcancer.2011.07.003","volume":"35","author":"JC Flanigan","year":"2011","unstructured":"Flanigan JC, Jilaveanu LB, Faries M et al (2011) Melanoma brain metastases: is it time to reassess the bias? Curr Probl Cancer 35:200\u2013210. https:\/\/doi.org\/10.1016\/j.currproblcancer.2011.07.003","journal-title":"Curr Probl Cancer"},{"key":"4754_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1200\/jco.18.00204","volume":"37","author":"HM Kluger","year":"2019","unstructured":"Kluger HM, Chiang V, Mahajan A et al (2019) Long-term survival of patients with Melanoma with active brain metastases treated with Pembrolizumab on a phase II trial. J Clin Oncol 37:52\u201360. https:\/\/doi.org\/10.1200\/jco.18.00204","journal-title":"J Clin Oncol"},{"key":"4754_CR5","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1016\/s1470-2045(20)30111-x","volume":"36","author":"SB Goldberg","year":"2018","unstructured":"Goldberg SB, Gettinger SN, Mahajan A et al (2018) Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab. J Clin Oncol 36:2009\u20132009. https:\/\/doi.org\/10.1016\/s1470-2045(20)30111-x","journal-title":"J Clin Oncol"},{"key":"4754_CR6","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ejca.2013.11.002","volume":"50","author":"R Dummer","year":"2014","unstructured":"Dummer R, Goldinger SM, Turtschi CP et al (2014) Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 50:611\u2013621. https:\/\/doi.org\/10.1016\/j.ejca.2013.11.002","journal-title":"Eur J Cancer"},{"key":"4754_CR7","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1200\/jco.2014.59.0539","volume":"33","author":"DB Costa","year":"2015","unstructured":"Costa DB, Shaw AT, Ou SH et al (2015) Clinical experience with Crizotinib in patients with Advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 33:1881\u20131888. https:\/\/doi.org\/10.1200\/jco.2014.59.0539","journal-title":"J Clin Oncol"},{"key":"4754_CR8","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/s1470-2045(12)70431-x","volume":"13","author":"GV Long","year":"2012","unstructured":"Long GV, Trefzer U, Davies MA et al (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13:1087\u20131095. https:\/\/doi.org\/10.1016\/s1470-2045(12)70431-x","journal-title":"Lancet Oncol"},{"key":"4754_CR9","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1093\/annonc\/mdw641","volume":"28","author":"GA McArthur","year":"2017","unstructured":"McArthur GA, Maio M, Arance A et al (2017) Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. Ann Oncol 28:634\u2013641. https:\/\/doi.org\/10.1093\/annonc\/mdw641","journal-title":"Ann Oncol"},{"key":"4754_CR10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/s1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin K, Ernstoff MS, Hamid O et al (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13:459\u2013465. https:\/\/doi.org\/10.1016\/s1470-2045(12)70090-6","journal-title":"Lancet Oncol"},{"key":"4754_CR11","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/s1470-2045(12)70324-8","volume":"13","author":"AM Di Giacomo","year":"2012","unstructured":"Di Giacomo AM, Ascierto PA, Pilla L et al (2012) Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 13:879\u2013886. https:\/\/doi.org\/10.1016\/s1470-2045(12)70324-8","journal-title":"Lancet Oncol"},{"key":"4754_CR12","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/s1470-2045(17)30429-1","volume":"18","author":"MA Davies","year":"2017","unstructured":"Davies MA, Saiag P, Robert C et al (2017) Dabrafenib plus Trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol 18:863\u2013873. https:\/\/doi.org\/10.1016\/s1470-2045(17)30429-1","journal-title":"Lancet Oncol"},{"key":"4754_CR13","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/nejmoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA, Forsyth PA, Algazi A et al (2018) Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med 379:722\u2013730. https:\/\/doi.org\/10.1056\/nejmoa1805453","journal-title":"N Engl J Med"},{"key":"4754_CR14","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/s1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long GV, Atkinson V, Lo S et al (2018) Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 19:672\u2013681. https:\/\/doi.org\/10.1016\/s1470-2045(18)30139-6","journal-title":"Lancet Oncol"},{"key":"4754_CR15","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.lungcan.2009.06.018","volume":"68","author":"A Bearz","year":"2010","unstructured":"Bearz A, Garassino I, Tiseo M et al (2010) Activity of pemetrexed on brain metastases from non-small cell lung cancer. Lung Cancer 68:264\u2013268. https:\/\/doi.org\/10.1016\/j.lungcan.2009.06.018","journal-title":"Lung Cancer"},{"key":"4754_CR16","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ijrobp.2014.02.022","volume":"89","author":"NK Gerber","year":"2014","unstructured":"Gerber NK, Yamada Y, Rimner A et al (2014) Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma. Int J Radiat Oncol Biol Phys 89:322\u2013329. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.02.022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4754_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.lungcan.2018.12.025","volume":"129","author":"L Crino","year":"2019","unstructured":"Crino L, Bronte G, Bidoli P et al (2019) Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer 129:35\u201340. https:\/\/doi.org\/10.1016\/j.lungcan.2018.12.025","journal-title":"Lung Cancer"},{"key":"4754_CR18","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.jtho.2019.02.009","volume":"14","author":"LEL Hendriks","year":"2019","unstructured":"Hendriks LEL, Henon C, Auclin E et al (2019) Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors. J Thorac Oncol 14:1244\u20131254. https:\/\/doi.org\/10.1016\/j.jtho.2019.02.009","journal-title":"J Thorac Oncol"},{"key":"4754_CR19","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/s1470-2045(15)00088-1","volume":"16","author":"H Okada","year":"2015","unstructured":"Okada H, Weller M, Huang R et al (2015) Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol 16:e534\u2013e542. https:\/\/doi.org\/10.1016\/s1470-2045(15)00088-1","journal-title":"Lancet Oncol"},{"key":"4754_CR20","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1200\/jco.2017.72.7511","volume":"35","author":"PY Wen","year":"2017","unstructured":"Wen PY, Chang SM, Van den Bent MJ et al (2017) Response assessment in neuro-oncology clinical trials. J Clin Oncol 35:2439\u20132449. https:\/\/doi.org\/10.1200\/jco.2017.72.7511","journal-title":"J Clin Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04754-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-024-04754-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-024-04754-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T14:43:28Z","timestamp":1724424208000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-024-04754-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["4754"],"URL":"https:\/\/doi.org\/10.1007\/s11060-024-04754-8","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,4]]},"assertion":[{"value":"10 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}